Article Details

Goldfinch Bio Announces Licensing Agreement with Takeda for CB1 Monoclonal Antibody for the ...

Retrieved on: 2019-10-02 18:52:30

Tags for this article:

Click the tags to see associated articles and topics

Goldfinch Bio Announces Licensing Agreement with Takeda for CB1 Monoclonal Antibody for the .... View article details on hiswai:

Excerpt

<div>Goldfinch Bio, headquartered in Cambridge, Massachusetts, was launched in 2016 by <b>Third Rock Ventures</b> and has an established strategic ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up